A comprehensive tumor microenvironment analysis uncovers key immune marker patterns that sharply distinguish cutaneous squamous cell carcinoma (cSCC) from basal cell carcinoma (BCC), pointing to new opportunities for clinical risk...
A comprehensive tumor microenvironment analysis uncovers key immune marker patterns that sharply distinguish cutaneous squamous cell carcinoma (cSCC) from basal cell carcinoma (BCC), pointing to new opportunities for clinical risk...
A study presented at the 2025 European Society for Medical Oncology Congress shows that first-line nivolumab significantly improves response rates in advanced basal cell carcinoma, offering new hope for patients beyond current second-line...
A study presented at the 2025 European Society for Medical Oncology Congress shows that first-line nivolumab significantly improves response rates in advanced basal cell carcinoma, offering new hope for patients beyond current second-line...
An international study reveals that patients with vitiligo experience varying levels of emotional and social burden, often independent of visible disease severity, underscoring the need for more holistic clinical assessments.
An international study reveals that patients with vitiligo experience varying levels of emotional and social burden, often independent of visible disease severity, underscoring the need for more holistic clinical assessments.
An exploratory analysis of a phase 2b trial highlights the potential benefits and protocol adjustments of combining ritlecitinib with narrow-band narrow-band ultraviolet B (UVB) phototherapy for enhanced repigmentation in nonsegmental...
An exploratory analysis of a phase 2b trial highlights the potential benefits and protocol adjustments of combining ritlecitinib with narrow-band narrow-band ultraviolet B (UVB) phototherapy for enhanced repigmentation in nonsegmental...
A recent study published by researchers utilizing data from the Adelphi Real World AD Disease Specific Programme™ provides a comprehensive assessment of the burden associated with mild-to-moderate atopic dermatitis (AD) in US adults.
A recent study published by researchers utilizing data from the Adelphi Real World AD Disease Specific Programme™ provides a comprehensive assessment of the burden associated with mild-to-moderate atopic dermatitis (AD) in US adults.
A novel treatment for stable vitiligo combining autologous skin cell suspension (ASCS) with phototherapy has demonstrated both clinical success and long-term cost savings when compared to phototherapy alone, according to study results...
A novel treatment for stable vitiligo combining autologous skin cell suspension (ASCS) with phototherapy has demonstrated both clinical success and long-term cost savings when compared to phototherapy alone, according to study results...
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
Individuals with vitiligo have an increased risk of major cardiovascular events, including stroke and venous thromboembolism, according to researchers.
A new artificial intelligence (AI) algorithm has demonstrated high accuracy in assessing facial vitiligo, offering a faster and more objective method for evaluating disease severity and treatment response, according to a study published in...
A new artificial intelligence (AI) algorithm has demonstrated high accuracy in assessing facial vitiligo, offering a faster and more objective method for evaluating disease severity and treatment response, according to a study published in...
The use of ruxolitinib cream for atopic dermatitis shows promise in decreasing the need for other treatments, with reductions in oral corticosteroid use observed in some patients.
The use of ruxolitinib cream for atopic dermatitis shows promise in decreasing the need for other treatments, with reductions in oral corticosteroid use observed in some patients.
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Patients with vitiligo in the US face significantly higher health care costs and resource utilization compared with the general population, according to a study published in the Journal of Investigative Dermatology.
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate and Editorial Board Member of First Report Managed Care—explores newly approved and existing anticoagulant therapies. He analyzes...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
